PlainRecalls
FDA Drug Moderate Class II Ongoing

Diltiazem Hydrochloride Extended-Release Capsules, USP 120 mg, Twice-a-Day Dosage, 100 Capsules per bottle, Rx Only, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ, 07430, Product of India, NDC 68462-562-01

Reported: April 10, 2024 Initiated: March 26, 2024 #D-0430-2024

Product Description

Diltiazem Hydrochloride Extended-Release Capsules, USP 120 mg, Twice-a-Day Dosage, 100 Capsules per bottle, Rx Only, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ, 07430, Product of India, NDC 68462-562-01

Reason for Recall

Failed Dissolution Specifications: Out of Specification (OOS) was reported in test of dissolution at the 12th month time point in long term stability study.

Details

Units Affected
6,528 bottles
Distribution
Nationwide in the US
Location
Mahwah, NJ

Frequently Asked Questions

What product was recalled?
Diltiazem Hydrochloride Extended-Release Capsules, USP 120 mg, Twice-a-Day Dosage, 100 Capsules per bottle, Rx Only, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ, 07430, Product of India, NDC 68462-562-01. Recalled by Glenmark Pharmaceuticals Inc., USA. Units affected: 6,528 bottles.
Why was this product recalled?
Failed Dissolution Specifications: Out of Specification (OOS) was reported in test of dissolution at the 12th month time point in long term stability study.
Which agency issued this recall?
This recall was issued by the FDA Drug on April 10, 2024. Severity: Moderate. Recall number: D-0430-2024.